News
BCAB
4.590
-6.52%
-0.320
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 2d ago
Weekly Report: what happened at BCAB last week (0406-0410)?
Weekly Report · 4d ago
Why Is Vanguard Total Stock Market ETF (VTI) Falling Today, 4/7/2026?
TipRanks · 04/07 12:45
Why Is Vanguard Total Stock Market ETF (VTI) Up Today, 4/6/2026?
TipRanks · 04/06 13:08
Weekly Report: what happened at BCAB last week (0330-0403)?
Weekly Report · 04/06 09:19
Upcoming Stock Splits This Week (April 6-10, 2026) – Stay Invested
TipRanks · 04/05 15:28
Vanguard Total Stock Market ETF (VTI) Daily Update, 4/3/26?
TipRanks · 04/03 13:27
BioAtla trading halted, news pending
TipRanks · 04/02 23:50
BioAtla Announces 1-for-50 Reverse Stock Split Merger
TipRanks · 04/02 21:00
BioAtla completes merger of BA Merger Sub into company effective April 6, 2026
Reuters · 04/02 20:09
Why Is Vanguard Total Stock Market ETF (VTI) Down Today, 4/2/26?
TipRanks · 04/02 12:14
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 04/01 17:06
Vanguard Total Stock Market ETF (VTI) Daily Snapshot — 4/1/26
TipRanks · 04/01 13:18
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 04/01 12:05
BioAtla Begins Strategic Review Following 2025 Results
TipRanks · 03/31 23:46
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 03/31 21:05
BioAtla Q4 EPS $(0.16) Beats $(0.30) Estimate, Sales $2.000M Beat $700.000K Estimate
Benzinga · 03/31 21:03
BioAtla announces 50-for-1 share consolidation
TipRanks · 03/31 20:45
BioAtla Q4 net loss narrows on lower expenses
Reuters · 03/31 20:31
BioAtla to implement 50-for-1 share consolidation
Seeking Alpha · 03/31 20:12
More
Webull provides a variety of real-time BCAB stock news. You can receive the latest news about Bioatla, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BCAB
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.